Proposed rule 2026-19349
Nonclinical Testing Terminology
The Food and Drug Administration (FDA, Agency, or we) is proposing to substitute references to "animal" tests or studies with "nonclinical" tests or studies, add a definition of the terms "nonclinical test" and "nonclinical study," and make other comparable or conforming amendments in certain safety and reporting sections of its regulations. The proposed rule would also substitute "nonclinical" for "preclinical" and "in vitro" for consistency in terminology. These proposed amendments align with recent amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) and are intended to remove an emphasis, in certain places, on the use of animal testing as the only scientific methodology to assess the safety of a drug in the nonclinical setting. These changes may also foster the development and use of scientifically valid new testing methodologies, potentially improving predictive accuracy of product safety testing while replacing, reducing, or refining animal use. The proposed rule would add no new requirements.
Source-supplied record
Document details
- Document number
- 2026-19349
- Published
- Sep 22, 2026
- Effective
- Not supplied
- Comments close
- Dec 7, 2026 (open)
- Federal Register citation
- 91 FR 60036
Docket identifiers
- Docket No. FDA-2026-N-5347
CFR references
- Title 21, part 312
- Title 21, part 314
- Title 21, part 315
- Title 21, part 361
- Title 21, part 601